利妥昔单抗对比环磷酰胺治疗结缔组织病相关间质性肺病:RECITAL 2b期试验
RECITAL 是一项在英国11个中心开展的双盲双模拟2b期随机对照试验,纳入101例严重或进展性结缔组织病相关间质性肺病(CTD-ILD)患者,比较利妥昔单抗与环磷酰胺的疗效。24周时两组用力肺活量(FVC)均较基线改善,但利妥昔单抗组与环磷酰胺组间主要终点差异无统计学意义(-40 mL,95%CI -153至74;利妥昔单抗组不良事件数较少,48周内糖皮质激素暴露更低。
要点
- 利妥昔单抗在改善24周FVC方面不优于环磷酰胺。
- 两组FVC和呼吸相关生活质量均有临床重要改善。
- 利妥昔单抗不良事件更少,可作为需静脉治疗者的替代选择。
核心结论
- 利妥昔单抗治疗CTD-ILD不优于环磷酰胺,但两组FVC和患者报告生活质量均有改善。
- 利妥昔单抗不良事件较少,应被视为需要静脉治疗的CTD-ILD患者的治疗替代选择。
研究设计与样本
- 随机、双盲、双模拟、2b期优效性试验,在英国11个专科ILD或风湿病中心招募18-80岁严重或进展性CTD-ILD患者。
- 101例患者按1:1随机分配至利妥昔单抗组(51例)或环磷酰胺组(50例),改良意向治疗人群分别为49例和48例。
主要发现
- 24周时环磷酰胺组FVC未调整平均增加99 mL(SD 329),利妥昔单抗组增加97 mL(SD 234)。
- 利妥昔单抗组报告445例不良事件,环磷酰胺组646例;严重不良事件分别为29例和33例。
关键数值与推荐
- 利妥昔单抗用法:第0周和第2周静脉给予1000 mg。
- 环磷酰胺用法:按体表面积600 mg/m2静脉给药,每4周一次,共6剂。
- 主要终点为24周FVC较基线的变化率,采用混合效应模型调整基线FVC和CTD类型。
临床怎么用
- 对于需要静脉治疗的CTD-ILD患者,利妥昔单抗可作为环磷酰胺的替代选择。
- 两种药物均可改善肺功能和生活质量,选择时需权衡不良反应和糖皮质激素暴露。
局限性
- 研究为2b期试验,样本量101例,可能不足以检测次要终点的组间差异。
- 随访至48周,长期疗效和安全性未报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rituximab is often used as rescue therapy in interstitial lung disease (ILD) associated with connective tissue disease (CTD), but has not been studied in clinical trials. This study aimed to assess whether rituximab is superior to cyclophosphamide as a treatment for severe or progressive CTD associated ILD. METHODS: We conducted a randomised, double-blind, double-dummy, phase 2b trial to assess the superiority of rituximab compared with cyclophosphamide. Patients aged 18-80 years with severe or progressive ILD related to scleroderma, idiopathic inflammatory myositis, or mixed CTD, recruited across 11 specialist ILD or rheumatology centres in the UK, were randomly assigned (1:1) to receive rituximab (1000 mg at weeks 0 and 2 intravenously) or cyclophosphamide (600 mg/m2 body surface area every 4 weeks intravenously for six doses). The primary endpoint was rate of change in forced vital capacity (FVC) at 24 weeks compared with baseline, analysed using a mixed-effects model with random intercepts, adjusted for baseline FVC and CTD type. Prespecified secondary endpoints reported in this Article were change in FVC at 48 weeks versus baseline; changes from baseline in 6 min walk distance, diffusing capacity of the lung for carbon monoxide (DLCO), physician-assessed global disease activity (GDA) score, and quality-of-life scores on the St George's Respiratory Questionnaire (SGRQ), King's Brief Interstitial Lung Disease (KBILD) questionnaire, and European Quality of Life Five-Dimension (EQ-5D) questionnaire at 24 and 48 weeks; overall survival, progression-free survival, and time to treatment failure; and corticosteroid use. All endpoints were analysed in the modified intention-to-treat population, which comprised all patients who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov (NCT01862926). FINDINGS: Between Dec 1, 2014, and March 31, 2020, we screened 145 participants, of whom 101 participants were randomly allocated: 50 (50%) to receive cyclophosphamide and 51 (50%) to receive rituximab. 48 (96%) participants in the cyclophosphamide group and 49 (96%) in the rituximab group received at least one dose of treatment and were included in analyses; 43 (86%) participants in the cyclophosphamide group and 42 (82%) participants in the rituximab group completed 24 weeks of treatment and follow-up. At 24 weeks, FVC was improved from baseline in both the cyclophosphamide group (unadjusted mean increase 99 mL [SD 329]) and the rituximab group (97 mL [234]); in the adjusted mixed-effects model, the difference in the primary endpoint at 24 weeks was -40 mL (95% CI -153 to 74; p=0·49) between the rituximab group and the cyclophosphamide group. KBILD quality-of-life scores were improved at 24 weeks by a mean 9·4 points (SD 20·8) in the cyclophosphamide group and 8·8 points (17·0) in the rituximab group. No significant differences in secondary endpoints were identified between the treatment groups, with the exception of change in GDA score at week 48, which favoured cyclophosphamide (difference 0·90 [95% CI 0·11 to 1·68]). Improvements in lung function and respiratory-related quality-of-life measures were observed in both treatment groups. Lower corticosteroid exposure over 48 weeks of follow-up was recorded in the rituximab group. Two (4%) of 48 participants who received cyclophosphamide and three (6%) of 49 who received rituximab died during the study, all due to complications of CTD or ILD. Overall survival, progression-free survival, and time to treatment failure did not significantly differ between the two groups. All participants reported at least one adverse event during the study. Numerically fewer adverse events were reported by participants receiving rituximab (445 events) than those receiving cyclophosphamide (646 events). Gastrointestinal and respiratory disorders were the most commonly reported adverse events in both groups. There were 62 serious adverse events of which 33 occurred in the cyclophosphamide group and 29 in the rituximab group. INTERPRETATION: Rituximab was not superior to cyclophosphamide to treat patients with CTD-ILD, although participants in both treatment groups had increased FVC at 24 weeks, in addition to clinically important improvements in patient-reported quality of life. Rituximab was associated with fewer adverse events. Rituximab should be considered as a therapeutic alternative to cyclophosphamide in individuals with CTD-ILD requiring intravenous therapy. FUNDING: Efficacy and Mechanism Evaluation Programme (Medical Research Council and National Institute for Health Research, UK).
引用
- Maher TM, Tudor VA, Saunders P, et al. Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial. Lancet Respir Med. 2022. PMID: 36375479. doi:10.1016/S2213-2600(22)00359-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。